tradmap

MYGN Myriad Genetics Inc

$4.54 +3.65%

Healthcare · In Vitro & In Vivo Diagnostic Substances

Myriad Genetics Inc (MYGN) is a healthcare company in the In Vitro & In Vivo Diagnostic Substances industry, with a market capitalization of $429 million. Shares last traded at $4.54, 47.1% below their 52-week high. Over the past year the stock is down 8.8%. Net profit margin is -44.4%, below the peer median of -3.8%. Revenue declined 1.6% year over year.

Market Cap
$429M
Shares Out
94.4M
EPS (TTM)
$-7.83
P/E Ratio
P/S Ratio
0.52
P/B Ratio
1.27
Dividend / Share
Dividend Yield
52-Week High
$8.58
52-Week Low
$3.53
Volume
153,562
Avg Vol (3m)
97,775.27

Performance

1W
-1.73%
1M
+28.25%
3M
-4.52%
6M
-34.06%
YTD
-26.18%
1Y
-8.84%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
55.33
SMA (50)
$4.41
SMA (200)
$5.87
Price vs SMA50
+2.87%
Price vs SMA200
-22.68%
ATR (14)
$0.28

Financials

Revenue
$825M
Net Income
$-366M
Gross Margin
69.9%
Operating Margin
-47.0%
Net Margin
-44.4%
Return on Equity
-108.5%
Return on Assets
-54.3%
Current Ratio
2.40
Debt / Equity
0.36
Revenue Growth (YoY)
-1.6%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.36 2026-05-06
FY 2025 $-3.95 2026-02-24
Q3 2025 $-3.88 2025-11-04
Q2 2025 $-3.59 2025-08-06
Q1 2026 $0.00 2026-05-06
FY 2025 $-1.41 2026-02-24

Full earnings history →

In Vitro & In Vivo Diagnostic Substances peers

MYGN vs 14 industry peers (In Vitro & In Vivo Diagnostic Substances), by market cap.

P/S vs peers
0.52 / 4.39 med
-88% discount
Net margin vs peers
-44.4% / -3.8% med
below median
1–14 of 14
IDXXIdexx Laboratories$44.3B41.8410.3024.6%+2.91%
LNTHLantheus Holdings, Inc.$6.8B28.974.3915.2%+0.67%
CLDXCelldex Therapeutics, Inc.$2.5B-9.84-1.47%
NTLAIntellia Therapeutics, Inc.$2.2B-5.30+2.25%
NEOGNeogen Corp$2.0B-1.85+4.14%
QDELQuidelortho Corp$932M+4.27%
ACHVAchieve Life Sciences, Inc.$496M-9.07-9.72%
MYGNMyriad Genetics Inc$429M-1.170.52-44.4%+3.65%
TKNOAlpha Teknova, Inc.$282M-16.326.95-42.6%+6.38%
IMDXInsight Molecular Diagnostics Inc.$176M-3510.5043.48-1.2%+2.25%
ICCCIMMUCELL CORP /DE/$86M-82.253.09-3.8%+0.53%
QCLSQ/C TECHNOLOGIES, INC.$32M-2.72+4.28%
VNRXVOLITIONRX LTD$12M-0.52+6.14%
CDIOCardio Diagnostics Holdings, Inc.$6M+2.53%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.